Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 26
    records per page

    Proteomics identifies a type I IFN, prothrombotic hyperinflammatory circulating COVID-19 neutrophil signature distinct from non-COVID-19 ARDS

    Authors: Leila Reyes; Manuel Alejandro Sanchez-Garcia; Tyler Morrison; Andrew JM Howden; Emily R Watts; Simone Arienti; Pranvera Sadiku; Patricia Coelho; Ananda S Mirchandani; David Hope; Sarah K Clark; Jo Singleton; Shonna Johnston; Robert Grecian; Azin Poon; Sarah McNamara; Isla Harper; Max Head Fourman; Alejandro J Brenes; Shalini Pathak; Amy Lloyd; Gio Rodriguez Blanco; Alex Von Kriegsheim; Bart Ghesquiere; Wesley Vermaelen; Camila T Cologna; Kevin Dhaliwal; Nik Hirani; David Dockrell; Moira KB Whyte; David M Griffith; Doreen A Cantrell; Sarah R Walmsley; Marc P. Hoeppner; Simon Imm; Ralf Juenker; Sina Kaiser; Ying H. Kan; Rainer Knoll; Christoph Lange; Georg Laue; Clemes Lier; Matthias Lindner; Georgios Marinos; Robert Markewitz; Jacob Nattermann; Rainer Noth; Peter Pickkers; Klaus F. Rabe; Alina Renz; Christoph Roecken; Jan Rupp; Annika Schaffarzyk; Alexander Scheffold; Jonas Schulte-Schrepping; Domagoj Schunck; Dirk Skowasch; Thomas Ulas; Klaus-Peter Wandinger; Michael Wittig; Johannes Zimmermann; Hauke Busch; Bimba F. Hoyer; Christoph Kaleta; Jan Heyckendorf; Matthijs Kox; Jan Rybniker; Stefan Schreiber; Joachim Schultze; Philip Rosenstiel; - HCA Lung Biological Network; - Deutsche COVID-19 Omics Initiative (DeCOI)

    doi:10.1101/2020.09.15.20195305 Date: 2020-09-18 Source: medRxiv

    Understanding the mechanisms by which infection with SARS-CoV-2 leads to acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD) is of significant clinical interest given the mortality associated with severe and critical coronavirus induced disease MESHD 2019 (COVID-19). Neutrophils play a key role in the lung injury MESHD characteristic of non-COVID-19 ARDS, but a relative paucity of these cells is observed at post-mortem in lung tissue of patients who succumb to infection MESHD with SARS-CoV-2. With emerging evidence of a dysregulated innate immune response in COVID-19, we undertook a functional proteomic survey of circulating neutrophil populations, comparing patients with COVID-19 ARDS, non-COVID-19 ARDS, moderate COVID-19, and healthy controls. We observe that expansion of the circulating neutrophil compartment and the presence of activated low and normal density mature and immature neutrophil populations occurs in both COVID-19 and non-COVID-19 ARDS. In contrast, release of neutrophil granule proteins, neutrophil activation of the clotting cascade and formation of neutrophil platelet aggregates is significantly increased in COVID-19 ARDS. Importantly, activation of components of the neutrophil type I IFN responses is specific to infection with SARS-CoV-2 and linked to metabolic rewiring. Together this work highlights how differential activation of circulating neutrophil populations may contribute to the pathogenesis of ARDS, identifying processes that are specific to COVID-19 ARDS.

    Respiratory Rehabilitation After Blood SERO Transfusion in a COVID-19 Patient: A Case Report

    Authors: Mohammad Javad Mousavi; Narges Obeidi; Saeed keshmiri; Farzan Azodi; Jamile Kiyani; Farhad Abbasi

    doi:10.21203/ Date: 2020-09-15 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has been identified as the most crucial threat of the century. Due to severe pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), the SARS-CoV-2 can cause shortness of breath MESHD, hypoxemia HP hypoxemia MESHD, and the need to mechanical ventilation, intensive care unit (ICU) management, and eventual death MESHD. We have tried to use a non-invasive approach to prevent patient from needing respiratory support with invasive ventilation (IV). Here, for the first time, improvement of oxygen delivery and oxygen saturation levels were observed in a COVID-19 patient using packed red blood SERO cells (PRBCs) transfusion.Case presentation: A 63-year-old man with a history of smoking and addiction who came to our hospital facility with fever HP fever MESHD, shortness of breath MESHD and decreased blood SERO oxygen saturation. High-resolution chest CT revealed bilateral and multifocal ground-glass opacities consistent with COVID-19. Subsequently, the COVID-19 infection was confirmed TRANS infection was confirmed MESHD by real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract. Conclusions: Oxygen delivery and oxygen saturation improvement were observed in the COVID-19 patient, after PRBCs transfusions.

    Diagnosis Challenges, Management, and Outcome of Infants Born to Mothers With COVID 19

    Authors: Gabriela Zaharie; Monica Hasmasanu; Daniel Muresan; Tunde Kovacs; Melinda Matyas

    doi:10.21203/ Date: 2020-08-25 Source: ResearchSquare

    Background: Severe acute respiratory distress HP respiratory distress MESHD syndrome with Coronavirus 2 (SARS-CoV-2) infection MESHD affected the pregnant women during the pandemics. Immunological particularity of this population and the increased need for medical assistance put this population in a high-risk category for SARS-Cov-2 infection MESHD.Because of high contamination risk and limited studies about vertical transmission TRANS, the labor and delivery of positive women require special conditions. Cesarean section is probably the best option for delivery of infants to reduce the risk of infection TRANS risk of infection TRANS infection MESHD during birth.Aim: Our study aims to present the management and outcome of infants born to mothers confirmed with coronavirus disease MESHD 2019 (COVID19) before delivery.Material and methods: This is longitudinal, retrospective study, analyzing demographics, laboratory data and management of neonates born of mothers with diagnosis of SARS-Cov -2 infection MESHD.Results: 5 neonates were born of SARS-Cov-2 positive mothers , all by C- section and had negative real time –PCR ( RT-PCR) test. None of them was breastfed during hospital stay. The negative RT-PCR test allowed us to reduce the hospital stay of infants and care them in non –isolated area.Conclusion: In our study, vertical or perinatal transmission TRANS of the infection was not present. The testing of the pregnant women, their isolation and delivery in safe conditions for the medical staff were possible, using adequate protection equipment to limit their infection and the risk TRANS infection and the risk TRANS infection and the risk MESHD for the newborns.

    Resilience in Cancer Care at the Time of COVID-19: Practical Approach to the Management of Cancer MESHD Patients During the COVID-19 Emergency in a Large Italian Community Hospital

    Authors: Angioletta Lasagna; Simona Secondino; Francesco Agustoni; Teresa Monaco; Ilaria Imarisio; Anna Pagani; Gianpiero Rizzo; Richard J. Tancredi; Emma Pozzi; Elisa Ferraris; Silvia Chiellino; Chiara Gandini; Silvia G. Brugnatelli; Paolo Pedrazzoli

    doi:10.21203/ Date: 2020-08-22 Source: ResearchSquare

    PurposeWith the emergence of coronavirus disease MESHD 2019 (COVID-19), the Oncologists have had to face the challenge of continuing active treatments without compromising the safety of our patients and healthcare personnel. Methods From February 24th, we reorganized our Oncology Unit with the introduction of a double-step triage strategy for cancer MESHD patients under treatment in order to identify patients at risk from COVID-19 and to avoid their admission to the outpatient clinic and to the inpatient ward.ResultsFrom February 24 to April 7 2020, we have performed 819 phone calls, leading to the authorization of 788 accesses (312 patients) to the outpatient clinic for active treatments. 26 patients (8.3%) with symptoms were kept at home and managed by repeated telephone calls; 23 of them were managed at home with symptomatic treatments and antibiotics and the others 3 were hospitalized for suspected COVID. At the second triage level, 5 patients weren’t admitted to the Outpatient clinic for persistent fever HP fever MESHD or respiratory distress HP respiratory distress MESHD.177 patients were admitted to the inpatient ward: none has been found to be COVID-19 positive and both outpatient and inpatient areas were still COVID-19 free. No healthcare workers became infected by SARS-CoV-2.ConclusionOur practical approach based on a simple double-step triage strategy, allows the identification of patients at risk for active COVID-19 infection MESHD, did not request neither human nor economic extra resources and appears effective, within a large community Hospital, in maintaining cancer MESHD care and therapy while protecting patients and healthcare workers from COVID-19 infection MESHD.

    Association of mental disorders MESHD with SARS-CoV-2 infection MESHD infection and severe HP health outcomes: a nationwide cohort study

    Authors: Ha-Lim Jeon; Jun Soo Kwon; So-Hee Park; Ju-Young Shin

    doi:10.1101/2020.08.05.20169201 Date: 2020-08-07 Source: medRxiv

    Background: No epidemiological data exists for the association between mental disorders MESHD and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD and coronavirus disease MESHD 2019 (COVID-19) severity. Aims: To evaluate the association between mental disorders MESHD and the risk of SARS-CoV-2 infection MESHD infection and severe HP outcomes following COVID-19. Methods: We performed a cohort study using the Korean COVID-19 patient database based on the national health insurance data. Each patient with a mental or behavioral disorder MESHD (diagnosed during six months prior to the first SARS-CoV-2 test) was matched by age TRANS, sex, and Charlson comorbidity index with up to four patients without mental disorders MESHD. SARS-CoV-2 positivity risk and risk of death MESHD or severe events (intensive care unit admission, use of mechanical ventilation, and acute respiratory distress syndrome MESHD respiratory distress HP syndrome) post-infection were calculated using conditional logistic regression analysis. Results: Among 230,565 patients tested for SARS-CoV-2, 33,653 (14.6%) had mental disorders MESHD, 928/33,653 (2.76%) tested positive, and 56/928 (6.03%) died. In multivariate analysis with the matched cohort, there was no association between mental disorders MESHD and SARS-CoV-2 positivity risk (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.92-1.12); however, a higher risk was associated with schizophrenia HP schizophrenia MESHD-related disorders (OR, 1.36; 95% CI, 1.02-1.81). Among confirmed cases TRANS, mortality risk significantly increased in patients with mental disorders MESHD (OR, 1.84, 95% CI, 1.07-3.15). Conclusion: Mental disorders MESHD are likely contributing factors of mortality following COVID-19. Although the infection risk TRANS infection risk TRANS did not increase in overall mental disorders MESHD, patients with schizophrenia HP schizophrenia MESHD-related disorders were more vulnerable to the infection MESHD.

    Sequential use of hemadsorption using Cytosorb® and Biosky® filter- technology in a COVID-19 patient suffering from severe ARDS MESHD 

    Authors: Matthias Mezger; Ingo Eitel; Stephan Ensminger; Dirk Pogorzalek; Zhipan Huang; Tobias Graf

    doi:10.21203/ Date: 2020-07-22 Source: ResearchSquare

    In March 2020, the World Health Organization (WHO) declared the novel c oronavirus disease MESHD(COVID- 19) pandemic. Here, we present the case of a patient who was admitted to our hospital with a cute respiratory distress syndrome MESHD respiratory distress HP syndrome (A RDS) MESHD following i nfection MESHDwith COVID-19. After initial stabilization through restrictive fluid management, hemadsorption using Cytosorb® was performed and finally temporary extubation of the patient was possible. However, the patient again clinically deteriorated and needed ventilation and finally ECMO-support and high catecholamine application. Whilst being on VV- ECMO, hemadsorption using Biosky® MG 350 filter was performed. In this manuscript, after a brief overview of the role of hemadsorption in A RDS, MESHD a detailed case presentation is followed by a critical discussion of the current literature.

    Acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient: a case report

    Authors: Edoardo Mattone; Maria Sofia; Elena Schembari; Valentina Palumbo; Rosario Bonaccorso; Valentina Randazzo; Gaetano La Greca; Carmelo Iacobello; Domenico Russello; Saverio Latteri

    doi:10.21203/ Date: 2020-07-13 Source: ResearchSquare

    Background coronavirus disease-19 (COVID-19) has spread to several countries around the world and has become an unprecedented pandemic. We report an extremely rare case of acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient.Case presentation: a COVID-19 patient was diagnosed with acute acalculous cholecystitis MESHD cholecystitis HP and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient’s clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous MESHD, the severe inflammation MESHD made surgery difficult to perform.Conclusions acalculous cholecystitis MESHD cholecystitis HP was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous MESHD histopathology pattern and the gallbladder wall ischemia MESHD was probably caused by vascular insufficiency MESHD secondary to severe acute respiratory distress syndrome MESHD respiratory distress HP syndrome of COVID-19 pneumonia MESHD pneumonia HP. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects MESHD small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and diarrhea HP diarrhea MESHD. Although the lack of evidence and guidelines about the management of patient with acute cholecystitis MESHD cholecystitis HP during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis MESHD cholecystitis HP on COVID-19 patients.

    COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial.

    Authors: Bruno Martins Tomazini; Israel S. Maia; Flavia R. Bueno; Maria Vitoria A. O. Silva; Franca P. Baldassare; Eduardo Leite V. Costa; Ricardo A. B. Moura; Michele Honorato; Andre N. Costa; Alexandre B. Cavalcanti; Regis Rosa; Alvaro Avezum; Viviane C. Veiga; Renato D. Lopes; Lucas P. Damiani; Flavia R. Machado; Otavio Berwanger; Luciano C. P. Azevedo

    doi:10.1101/2020.06.24.20139303 Date: 2020-06-26 Source: medRxiv

    OBJECTIVES: The infection MESHD caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV2 infection MESHD (Coronavirus disease 2019 - COVID-19) is viral pneumonia HP pneumonia MESHD with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress HP Respiratory Distress MESHD Syndrome ( ARDS MESHD). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult TRANS patients with moderate or severe ARDS MESHD due to confirmed or probable COVID-19. METHODS: This is a pragmatic, prospective, randomized, stratified, multicenter, open-label, controlled trial including 350 patients with early-onset (less than 48h before randomization) moderate or severe ARDS MESHD, defined by the Berlin criteria, due to COVID-19. Eligible patients will be randomly allocated to either standard treatment plus dexamethasone (intervention group) or standard treatment without dexamethasone (control group). Patients in the intervention group will receive dexamethasone 20mg IV once daily for 5 days, followed by dexamethasone 10mg IV once daily for additional 5 days or until Intensive Care Unit (ICU) discharge, whichever occurs first. The primary outcome is ventilator-free days within 28 days after randomization, defined as days alive and free from invasive mechanical ventilation. Secondary outcomes are all-cause mortality rates at day 28, evaluation of the clinical status at day 15 assessed with a 6-level ordinal scale, mechanical ventilation duration from randomization to day 28, Sequential Organ Failure Assessment (SOFA) Score evaluation at 48h, 72h and 7 days and ICU-free days within 28. ETHICS AND DISSEMINATION: This trial was approved by the Brazilian National Committee of Ethics in Research (Comissao Nacional de Etica em Pesquisa - CONEP) and National Health Surveillance Agency (ANVISA). An independent data monitoring committee will perform interim analyses and evaluate adverse events throughout the trial. Results will be submitted for publication after enrolment and follow-up are complete.

    SARS-CoV-2 assays to detect functional antibody SERO responses that block ACE2 recognition in vaccinated animals and infected MESHD patients

    Authors: Daniel W Kulp; Susanne Walker; Neethu Chokkalingam; Emma L Reuschel; Mansi Purwar; Ziyang Xu; Ebony Y Gary; Kevin Y. Kim; Katherine Schultheis; Jewell Walters; Stephanie Ramos; Trevor R.F. Smith; Kate Broderick; Pablo Tebas; Ami Patel; David B Weiner

    doi:10.1101/2020.06.17.158527 Date: 2020-06-20 Source: bioRxiv

    SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2 MESHD) has caused a global pandemic of COVID-19 resulting in cases of mild to severe respiratory distress HP and significant mortality. The global outbreak of this novel coronavirus has now infected >8 million people worldwide with >2 million cases in the US (June 17th, 2020). There is an urgent need for vaccines and therapeutics to combat the spread of this coronavirus. Similarly, the development of diagnostic and research tools to determine infection MESHD and vaccine efficacy are critically needed. Molecular assays have been developed to determine viral genetic material present in patients. Serological assays SERO have been developed to determine humoral responses to the spike protein or receptor binding domain (RBD). Detection of functional antibodies SERO can be accomplished through neutralization of live SARS-CoV2 virus, but requires significant expertise, an infectible stable cell line, a specialized BioSafety Level 3 (BSL-3) facility. As large numbers of people return from quarantine, it is critical to have rapid diagnostics that can be widely adopted and employed to assess functional antibody SERO levels in the returning workforce. This type of surrogate neutralization diagnostic can also be used to assess humoral immune responses induced in patients from the large number of vaccine and immunotherapy trials currently on-going. Here we describe a rapid serological diagnostic assay for determining antibody SERO receptor blocking and demonstrate the broad utility of the assay by measuring the antibody SERO functionality of sera from small animals and non-human primates immunized with an experimental SARS-CoV-2 vaccine and using sera from infected patients.

    Critical Complications of COVID-19: A systematic Review and Meta-Analysis study

    Authors: Kimia Vakili; Mobina Fathi; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Aiyoub Pezeshgi

    doi:10.1101/2020.06.14.20130955 Date: 2020-06-16 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a novel coronavirus infection MESHD that has spread worldwide in a short period and caused a pandemic. The goal of this meta-analysis is to evaluate the prevalence SERO of most common symptoms and complications of COVID-19. Methods: All related studies assessing the clinical complications of COVID-19 have been identified through web search databases (PubMed and Scopus). Relevant data were extracted from these studies and analyzed by stata (ver 14) random-effects model. The heterogeneity of studies were assessed by I2 index. The publication bias was examined by Funnel plots and Eggers test. Results: 30 studies were in our meta-analysis including 6 389 infected MESHD patients. The prevalence SERO of most common symptoms were: fever HP 84.30% (95% CI: 77.13-90.37; I2=97.74%), cough HP 63.01% (95% CI: 57.63-68.23; I2=93.73%), dyspnea HP dyspnea MESHD 37.16% (95% CI: 27.31-47.57%; I2=98.32%), fatigue HP fatigue MESHD 34.22% (95% CI: 26.29-42.62; I2=97.29%) and diarrhea HP diarrhea MESHD 11.47 %(95% CI: 6.96-16.87; I2=95.58%), respectively. The most prevalent complications were acute respiratory distress HP syndrome (ARDS) 33.15% (95% CI: 23.35-43.73; I2=98.56%), acute cardiac injury 13.77% (95% CI: 9.66-18.45; I2=91.36%), arrhythmia HP 16.64% (95% CI: 9.34-25.5; I2=92.29%), heart failure 11.50% (95% CI: 3.45-22.83; I2=89.48%), and acute kidney injury HP (AKI) 8.40 %(95% CI: 5.15-12.31; I2=95.22%, respectively. According to our analysis, mortality rate of COVID-19 patients were 12.29% (95% CI: 6.20-19.99; I2=98.29%). Conclusion: We assessed the prevalence SERO of the main clinical complications of COVID-19 and found that after respiratory complications, cardiac and renal complications are the most common clinical complications of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.